Our Technology Portfolio
Probingon commercialises validated microwave and intrabody sensing technologies originating from the Microwaves in Medical Engineering Group (MMG) at Uppsala University’s Ångström Laboratory. MMG advances technologies from early research through to TRL 4; Probingon takes over from TRL 5 and drives each technology through to commercial launch via OEM licensing or device distribution. The portfolio reflects more than a decade of foundational research in how microwave signals interact with biological tissue, a physical domain that yields both communication and diagnostic capability from the same underlying science.
The company operates two commercial tracks, both funded primarily through non-dilutive EU and Swedish research grants, with the licensing business as the primary financial model for investors.
Track 1: FAT-IBC — Intrabody Communication Layer
FAT-IBC (Fat-tissue Intra-Body Communication) is Probingon’s primary commercial asset and the basis of the current investment round. It is a wireless communication subsystem that uses the natural waveguiding properties of subcutaneous fat tissue at 2.4 GHz to create a secure, cable-free data channel between independent implanted nodes inside the body.
No existing wireless standard achieves reliable in-body communication between spatially separated implanted devices. FAT-IBC resolves this constraint, making distributed multi-node implant architectures possible for the first time. The immediate commercial application is spinal cord stimulation, where the same constraint is most acute and the OEM base is well-established. The physical layer extends across bioelectric medicine wherever independent implanted nodes need to communicate.
FAT-IBC is licensed to OEM manufacturers of implantable medical devices. The OEM carries the clinical programme, the regulatory pathway, and the reimbursement strategy. Probingon’s obligation is the communication layer and integration support.
Validated performance: 92 Mb/s sustained throughput (IEEE TBME 2024); flexible wearable antenna system validated in human volunteer trials with SAR confirmed at 0.3061 W/kg (Scientific Reports, Nature Portfolio 2026); TRL 6 demonstrated within H2020 B-CRATOS and independently assessed by an EU expert panel.
Read more about FAT-IBC and Body Area Networks
Track 2: MAS — Microwave Muscle Analyser
The Muscle Analyser System (MAS) is a handheld, non-invasive diagnostic device being developed to quantify muscle mass and fat infiltration in skeletal muscle using non-ionising microwaves. Rather than relying on ionising radiation or bulky imaging equipment, MAS is designed to analyse how microwave signals propagate through and reflect from tissue layers, extracting dielectric properties that correlate with muscle composition at the point of care.
The technology was initially developed for sarcopenia diagnostics, where the absence of accessible, radiation-free muscle quality measurement is a recognised clinical gap. Its intended utility extends into any condition where skeletal muscle deterioration is a primary clinical concern: surgical recovery, COPD, congestive heart failure, chronic kidney disease, cancer cachexia, and liver disease. In each of these settings, accessible and repeatable muscle composition data at the point of care would support earlier intervention and more objective therapy monitoring than current standard practice allows.
MAS is being developed under the Eurostars-funded DIAMPS programme, a consortium commercially led by Probingon. The programme advances the device through clinical validation toward CE marking and commercial launch, with Probingon responsible for product development, regulatory strategy, and commercialisation. The MAS name reflects academic origins; the commercial product name will be confirmed ahead of launch.